Skip to main content

Advertisement

SpringerLink
Log in

Cutaneous T-cell lymphoma: Biologic targets for therapy

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Cutaneous T-cell lymphoma (CTCL) is a malignancy derived from a clonal population of mature, skin-homing lymphocytes. In the skin, the CTCL cells are associated with the Langerhans cells and respond to protumor cytokines. In turn, they upregulate T-cell receptor-dependent signaling pathways and subsequently demonstrate stigmata of T-cell activation. As the disease progresses, there appears to be an accumulation of genetic and epigenetic changes that may contribute to the aggressiveness of the disease. Furthermore, the persistence of tumor appears to require escape from cancer immunosurveillance. This process likely requires modulation of the host immune system and skewing of the immune cells away from a cytotoxic phenotype. Each of these steps in disease pathogenesis offers a potential object for targeted therapies. This article reviews the recent research into the design and use of targeted therapies for CTCL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Willemze R, Jaffe ES, Burg G, et al.: WHO-EORTC classification for cutaneous lymphomas. Blood 2005, 105:3768–3785.

    Article  PubMed  CAS  Google Scholar 

  2. Girardi M, Heald PW, Wilson LD: The pathogenesis of mycosis fungoides. N Engl J Med 2004, 350:1978–1988.

    Article  PubMed  CAS  Google Scholar 

  3. Kim EJ, Hess S, Richardson SK, et al.: Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest 2005, 115:798–812.

    Article  PubMed  CAS  Google Scholar 

  4. Mao X, Lillington D, Scarisbrick JJ, et al.: Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sézary syndrome and mycosis fungoides. Br J Dermatol 2002, 147:464–475.

    Article  PubMed  CAS  Google Scholar 

  5. Frankfurt O, Rosen ST: Mechanisms of glucocorticoid-induced apoptosis in hematologic malignancies: updates. Curr Opin Oncol 2004, 16:553–563.

    Article  PubMed  CAS  Google Scholar 

  6. Zackheim HS, Kashani-Sabet M, Amin S: Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol 1998, 134:949–954.

    Article  PubMed  CAS  Google Scholar 

  7. Whittaker SJ, Foss FM: Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sézary syndrome variants of cutaneous T-cell lymphoma. Cancer Treat Rev 2007, 33:146–160.

    Article  PubMed  CAS  Google Scholar 

  8. Weichenthal M, Schwarz T: Phototherapy: How does UV work? Photodermatol Photoimmunol Photomed 2005, 21:260–266.

    Article  PubMed  CAS  Google Scholar 

  9. Jones GW, Hoppe RT, Glatstein E: Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9:1057–1076.

    PubMed  CAS  Google Scholar 

  10. Schramm VL: Development of transition state analogues of purine nucleoside phosphorylase as anti-T-cell agents. Biochim Biophys Acta 2002, 1587:107–117.

    PubMed  CAS  Google Scholar 

  11. Balakrishnan K, Nimmanapalli R, Ravandi F, et al.: Forodesine, an inhibitor of purine nucleoside phosphorylase, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2006, 108:2392–2398.

    Article  PubMed  CAS  Google Scholar 

  12. Olsen E, Duvic M, Frankel A, et al.: Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001: 19:376–388.

    PubMed  CAS  Google Scholar 

  13. Foss F, Demierre MF, DiVenuti G: A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2005, 106:454–457.

    Article  PubMed  CAS  Google Scholar 

  14. Druker BJ, Guilhot F, O’Brien SG, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006, 355:2408–2417.

    Article  PubMed  CAS  Google Scholar 

  15. McGregor JM, Crook T, Fraser-Andrews EA, et al.: Spectrum of p53 gene mutations suggests a possible role for ultraviolet radiation in the pathogenesis of advanced cutaneous lymphomas. J Invest Dermatol 1999, 112:317–321.

    Article  PubMed  CAS  Google Scholar 

  16. Kari L, Loboda A, Nebozhyn M, et al.: Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003, 197:1477–1488.

    Article  PubMed  CAS  Google Scholar 

  17. Scarisbrick JJ, Mitchell TJ, Calonje E, et al.: Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. J Invest Dermatol 2003, 121:894–901.

    Article  PubMed  CAS  Google Scholar 

  18. Scarisbrick JJ, Woolford AJ, Calonje E, et al.: Frequent abnormalities of the p15 and p16 genes in mycosis fungoides and Sézary syndrome. J Invest Dermatol 2002, 118:493–499.

    Article  PubMed  CAS  Google Scholar 

  19. van Doorn R, Zoutman WH, Dijkman R, et al.: Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol 2005, 23:3886–3896.

    Article  PubMed  CAS  Google Scholar 

  20. Marks PA: The mechanism of the anti-tumor activity of the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA). Cell Cycle 2004, 3:534–535.

    PubMed  CAS  Google Scholar 

  21. Duvic M, Talpur R, Ni X, et al.: Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109:31–39.

    Article  PubMed  CAS  Google Scholar 

  22. Berger CL, Hanlon D, Kanada D, et al.: The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 2002, 99:2929–2939.

    PubMed  CAS  Google Scholar 

  23. Edelson RL: Cutaneous T cell lymphoma: the helping hand of dendritic cells. Ann N Y Acad Sci 2001, 941:1–11.

    Article  PubMed  CAS  Google Scholar 

  24. Yamanaka K, Clark R, Rich B, et al.: Skin-derived interleukin-7 contributes to the proliferation of lymphocytes in cutaneous T-cell lymphoma. Blood 2006, 107:2440–2445.

    Article  PubMed  CAS  Google Scholar 

  25. Ortonne N, Huet D, Gaudez C, et al.: Significance of circulating T-cell clones in Sézary syndrome. Blood 2006, 107:4030–4038.

    Article  PubMed  CAS  Google Scholar 

  26. Rook AH, Kuzel TM, Olsen EA: Cytokine therapy of cutaneous T-cell lymphoma: interferons, interleukin-12, and interleukin-2. Hematol Oncol Clin North Am 2003, 17:1435–1448, ix.

    Article  PubMed  Google Scholar 

  27. Hoppe RT, Medeiros LJ, Warnke RA, et al.: CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995, 32:448–453.

    Article  PubMed  CAS  Google Scholar 

  28. Wysocka M, Benoit BM, Newton S, et al.: Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15. Blood 2004, 104:4142–4149.

    Article  PubMed  CAS  Google Scholar 

  29. Yawalkar N, Ferenczi K, Jones DA, et al.: Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 2003, 102:4059–4066.

    Article  PubMed  CAS  Google Scholar 

  30. Axelrod PI, Lorber B, Vonderheid EC: Infections complicating mycosis fungoides and Sézary syndrome. JAMA 1992, 267:1354–1358.

    Article  PubMed  CAS  Google Scholar 

  31. Mao X, Orchard G, Lillington DM, et al.: BCL2 and JUNB abnormalities in primary cutaneous lymphomas. Br J Dermatol 2004, 151:546–556.

    Article  PubMed  CAS  Google Scholar 

  32. Zic JA: The treatment of cutaneous T-cell lymphoma with photopheresis. Dermatol Ther 2003, 16:337–346.

    Article  PubMed  Google Scholar 

  33. Berger CL, Xu AL, Hanlon D, et al.: Induction of human tumor-loaded dendritic cells. Int J Cancer 2001, 91:438–447.

    Article  PubMed  CAS  Google Scholar 

  34. Moor AC, Schmitt IM, Beijersbergen van Henegouwen GM, et al.: Treatment with 8-MOP and UVA enhances MHC class I synthesis in RMA cells: preliminary results. J Photochem Photobiol B 1995, 29:193–198.

    Article  PubMed  CAS  Google Scholar 

  35. Perez MI, Edelson RL, John L, et al.: Inhibition of antiskin allograft immunity induced by infusions with photoinactivated effector T lymphocytes (PET cells). Yale J Biol Med 1989, 62:595–609.

    PubMed  CAS  Google Scholar 

  36. Berger CL, Wang N, Christensen I, et al.: The immune response to class I-associated tumor-specific cutaneous T-cell lymphoma antigens. J Invest Dermatol 1996, 107:392–397.

    Article  PubMed  CAS  Google Scholar 

  37. Edelson R, Berger C, Gasparro F, et al.: Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987, 316:297–303.

    Article  PubMed  CAS  Google Scholar 

  38. Dunn GP, Koebel CM, Schreiber RD: Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006, 6:836–848.

    Article  PubMed  CAS  Google Scholar 

  39. Takaoka A, Hayakawa S, Yanai H, et al.: Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003, 424:516–523.

    Article  PubMed  CAS  Google Scholar 

  40. Rook AH, Wood GS, Yoo EK, et al.: Interleukin-12 therapy of cutaneous T-cell lymphoma induces lesion regression and cytotoxic T-cell responses. Blood 1999, 94:902–908.

    PubMed  CAS  Google Scholar 

  41. Suchin KR, Cucchiara AJ, Gottleib SL, et al.: Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol 2002, 138:1054–1060.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, 06520, USA

    Francine Foss

Authors
  1. Jaehyuk Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francine Foss
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francine Foss.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Choi, J., Foss, F. Cutaneous T-cell lymphoma: Biologic targets for therapy. Curr Hematol Malig Rep 2, 272–277 (2007). https://doi.org/10.1007/s11899-007-0037-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-007-0037-8

Keywords

Search

Navigation